Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 14/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060293 | 0.89 | NOS2 (0.71) | NOS2 | |
| SCHEMBL7059749 | 0.82 | NOS2 (0.54) | NOS2 | |
| SCHEMBL5195165 | 0.82 | NOS2 (0.62) | NOS2CTSLCTSSCTSKGAA | |
| SCHEMBL6296471 | 0.82 | NOS2 (0.68) | NOS2 | |
| SCHEMBL5195163 | 0.81 | NOS2 (0.69) | NOS2 | |
| SCHEMBL5190161 | 0.79 | NOS2 (0.92) | NOS2 | |
| SCHEMBL5190715 | 0.79 | NOS2 (0.62) | NOS2GAA | |
| SCHEMBL5191333 | 0.78 | NOS2 (0.78) | NOS2 | |
| SCHEMBL5190708 | 0.78 | NOS2 (0.69) | NOS2 | |
| SCHEMBL5195158 | 0.77 | NOS2 (0.75) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864263-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6846829-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6747031-B2 | MUSCLE RELAXANTS, CONTROLLING IMMUNOLOGY, STROKES, ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2004-06-08 | — | — | US | disclosed |
| US-6670473-B2 | Inhibitors of nitric oxide synthase (nos) | BERLEX LABORATORIES, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-24 | — | — | US | disclosed |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-03-27 | — | — | US | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885CTSL 3697/4885CTSS 1934/4885 |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885CTSL 3697/4885CTSS 1934/4885 |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885CTSL 3697/4885CTSS 1934/4885 |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885CTSL 3697/4885CTSS 1934/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885CTSL 3697/4885CTSS 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.